Table 1. Differentially expressed genes upon BYL719 treatment in patients with metastatic breast cancer.

Paired biopsies of tumors from ER-positive breast cancer patients receiving BYL719 as part of a clinical trial were collected before and during treatment. RNA was extracted, and the expression of 105 breast cancer–specific genes was analyzed using the nCounter platform. Differentially expressed genes (FDR ≤ 25%) between on-treatment and pretreatment biopsies are shown.

Gene IDScore (d)Fold changeq (%)
GRB72.1771.2730.000
BCL22.1501.3630.000
MDM22.0461.2770.000
CXXC51.7701.27711.478
PGR1.5601.35914.667
ESR11.4521.55414.667
ACTR3B1.3901.17614.667
SFRP11.2891.26617.742
ERBB21.2091.14417.742
SLC39A61.0341.14019.556
PHGDH0.9991.25319.556
FOXA10.9081.10319.556
FGFR40.8901.26919.556
GPR1600.8741.13419.556
FOXC10.6531.15722.564
MLPH0.6411.08222.564
MAPT0.6221.12422.564
BIRC5−2.009−1.21911.478
MYBL2−1.946−1.22611.478
EXO1−1.544−1.19011.478
CENPF−1.424−1.20211.478
CEP55−1.280−1.17211.478
TYMS−1.276−1.13011.478
RRM2−1.265−1.20811.478
CDH3−1.261−1.31711.478
MKI67−1.227−1.14811.478
MELK−1.164−1.14911.478
CCNE1−1.155−1.12111.478
UBE2T−1.137−1.13111.478
KIF2C−1.111−1.16411.478
KNTC2−1.032−1.10411.478
CDCA1−0.997−1.13011.478
ORC6L−0.988−1.13611.478
CDC6−0.924−1.14311.478
CDC20−0.886−1.10611.478
CCNB1−0.871−1.09311.478
PTTG1−0.759−1.09814.667
ANLN−0.673−1.09617.742
MMP11−0.619−1.11417.742